Bogari Hanin, Patanwala Asad E, Cosgrove Richard, Katz Michael
Department of Pharmacy Practice & Science, College of Pharmacy, The University of Arizona, 1295N Martin Ave, PO Box 210202, Tucson, AZ, 85721, USA.
Thromb Res. 2014 Dec;134(6):1220-3. doi: 10.1016/j.thromres.2014.09.031. Epub 2014 Oct 2.
There is a lack of evidence regarding the need for thromboprophylaxis in hospitalized patients with liver disease. The purpose of this study was to evaluate the Padua Predictor Score (PPS) as a risk-stratification tool for the development of venous thromboembolism (VTE) in patients with chronic liver disease.
This was a retrospective cohort study conducted in an academic medical center in the United States. Consecutive adult patients admitted with chronic liver disease were included. Patients were categorized into two groups based on whether they developed a VTE or not. The risk for VTE in each patient was evaluated using the Padua Predictor Score (PPS). Patients were risk stratified using the PPS score as high-risk (score ≥4) and low-risk (score <4). The risk of VTE based on PPS categorization was evaluated using logistic regression.
A total of 163 patients with liver disease were included in the study cohort. Of these, 18 (11%) developed VTE. Mean PPS was significantly greater in the VTE group than the non-VTE group (5.8 ± 2.0 versus 3.0 ± 2.1, respectively; p<0.001). In high-risk patients 22% (n=16/72) developed VTE and in low-risk patients 2% (2/91) developed VTE (p<0.001). High-risk patients were more likely to have VTE (OR 12.7, 95% CI 2.8 to 57.4, p=0.001).
The PPS is an effective risk assessment tool for VTE in patients hospitalized with chronic liver disease.
关于肝病住院患者是否需要进行血栓预防,目前缺乏证据。本研究的目的是评估帕多瓦预测评分(PPS)作为慢性肝病患者发生静脉血栓栓塞(VTE)的风险分层工具。
这是一项在美国一家学术医疗中心进行的回顾性队列研究。纳入连续收治的成年慢性肝病患者。根据患者是否发生VTE将其分为两组。使用帕多瓦预测评分(PPS)评估每位患者发生VTE的风险。根据PPS评分将患者分为高危(评分≥4)和低危(评分<4)进行风险分层。使用逻辑回归评估基于PPS分类的VTE风险。
研究队列共纳入163例肝病患者。其中,18例(11%)发生了VTE。VTE组的平均PPS显著高于非VTE组(分别为5.8±2.0和3.0±2.1;p<0.001)。高危患者中22%(n=16/72)发生VTE,低危患者中2%(2/91)发生VTE(p<0.001)。高危患者发生VTE的可能性更大(OR 12.7,95%CI 2.8至57.4,p=0.001)。
PPS是慢性肝病住院患者VTE的有效风险评估工具。